MX341547B - Péptidos pan-antivirales para la inhibición de proteína quinasa. - Google Patents
Péptidos pan-antivirales para la inhibición de proteína quinasa.Info
- Publication number
- MX341547B MX341547B MX2012008448A MX2012008448A MX341547B MX 341547 B MX341547 B MX 341547B MX 2012008448 A MX2012008448 A MX 2012008448A MX 2012008448 A MX2012008448 A MX 2012008448A MX 341547 B MX341547 B MX 341547B
- Authority
- MX
- Mexico
- Prior art keywords
- pan
- protein kinase
- kinase inhibition
- antiviral peptides
- protein kinases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
La presente invención se refiere a un método para inhibir proteína quinasas al administrar polipéptidos derivados de la alfa-neurotoxina y al inhibir proteína quinasas. Las enfermedades tratadas de esta manera incluyen cáncer, influenza, síndrome de Tourette, dolor y déficits neurológicos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/691,902 US7807635B1 (en) | 2010-01-22 | 2010-01-22 | Pan-antiviral peptides for protein kinase inhibition |
US12/897,087 US9220743B2 (en) | 2010-01-22 | 2010-10-04 | Pan-antiviral peptides for protein kinase inhibition |
PCT/US2011/022200 WO2011091344A1 (en) | 2010-01-22 | 2011-01-24 | Pan-antiviral peptides for protein kinase inhibition |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012008448A MX2012008448A (es) | 2013-02-07 |
MX341547B true MX341547B (es) | 2016-08-24 |
Family
ID=44307254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012008448A MX341547B (es) | 2010-01-22 | 2011-01-24 | Péptidos pan-antivirales para la inhibición de proteína quinasa. |
Country Status (7)
Country | Link |
---|---|
US (2) | US9220743B2 (es) |
EP (1) | EP2525804B1 (es) |
AU (1) | AU2011207419A1 (es) |
CA (1) | CA2787812C (es) |
IL (1) | IL221065A (es) |
MX (1) | MX341547B (es) |
WO (1) | WO2011091344A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7259237B1 (en) * | 2006-12-29 | 2007-08-21 | Miller Kent D | Pan-antiviral peptides |
US9220743B2 (en) * | 2010-01-22 | 2015-12-29 | Nuovo Biologics, Llc | Pan-antiviral peptides for protein kinase inhibition |
EP4361606A2 (en) | 2012-02-03 | 2024-05-01 | California Institute of Technology | Signal encoding and decoding in multiplexed biochemical assays |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3888877A (en) | 1969-06-11 | 1975-06-10 | Schering Corp | Macrocyclic compounds and complexes thereof |
US3888977A (en) | 1973-02-01 | 1975-06-10 | Murray J Sanders | Modified neurotoxin |
US4162303A (en) | 1977-06-17 | 1979-07-24 | Sanders Murray J | Potency and atoxicity test for modified neurotoxin |
US4126676A (en) | 1977-07-22 | 1978-11-21 | Sanders Murray J | Modified neurotoxin derived from naja genus snake venom |
US4341762A (en) | 1981-04-07 | 1982-07-27 | Haast William E | Use of snake venoms for treatment of neurological and related disorders |
US4741902A (en) | 1986-07-14 | 1988-05-03 | Haast William E | Compositions for treatment of neurological and related disorders |
US5182260A (en) | 1989-01-27 | 1993-01-26 | Biogen, Inc. | Dna sequences encoding snake venom inhibitors of platelet activation processes for producing those inhibitors and compositions using them |
US5120639A (en) | 1989-04-03 | 1992-06-09 | E. R. Squibb & Sons, Inc. | Selective inhibition of dna polymerase |
US5676974A (en) | 1992-10-23 | 1997-10-14 | Santiago H. Valdes | Pharmaceutical compositions containing giroxina and phospholipase A2 and methods of increasing a patient's CD4 count using the pharmaceutical compositions |
US5565431A (en) | 1994-06-20 | 1996-10-15 | Lipps; Binie V. | Cancer cell inhibitors and method |
US5723477A (en) | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US20020028798A1 (en) | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
CA2253937A1 (en) | 1996-05-10 | 1997-11-20 | Phylomed Corporation | Methods for oxidizing disulfide bonds using ozone |
US20030211465A1 (en) | 1996-05-10 | 2003-11-13 | Mundschenk David D. | Immunokine composition and method |
US5994515A (en) | 1996-06-25 | 1999-11-30 | Trustees Of The University Of Pennsylvania | Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
US5955303A (en) | 1997-03-06 | 1999-09-21 | Incyte Pharmaceuticals, Inc. | Human chemokine receptor-like protein |
SG129211A1 (en) | 1997-11-06 | 2007-02-26 | Univ Singapore | Therapeutic molecules |
AU2001249194A1 (en) | 2000-03-23 | 2001-10-03 | Phylomed Corporation | Immunokine composition and method |
DE60124915T2 (de) | 2000-07-11 | 2007-11-29 | Binie V. Belaire Lipps | Synthetische peptide gegen neurologische krankheiten |
DE10035854A1 (de) | 2000-07-24 | 2002-02-07 | Bayer Ag | Schlangentoxin und dessen Verwendung als Arzneimittel |
CN1194011C (zh) | 2000-08-03 | 2005-03-23 | 上海中科伍佰豪生物工程有限公司 | 眼镜蛇短链神经毒素的制法和用途 |
AUPR409401A0 (en) | 2001-03-29 | 2001-04-26 | University Of Melbourne, The | Analgesic compound |
US20040192594A1 (en) | 2002-01-28 | 2004-09-30 | Paul Reid | Modified neurotoxins as therapeutic agents for the treatment of diseases and methods of making |
US20050031608A1 (en) | 2003-08-06 | 2005-02-10 | Paul Reid | Modified alpha-neurotoxins as painkillers |
US20050255097A1 (en) | 2004-01-26 | 2005-11-17 | Paul Reid | Modified venom and venom components as anti-retroviral agents |
US8034777B2 (en) | 2004-09-23 | 2011-10-11 | Receptopharm, Inc. | Modified anticholinergic neurotoxins as modulators of the autoimmune reaction |
US20060088858A1 (en) | 2004-10-25 | 2006-04-27 | Reid Paul F | Modified venom and venom components as anti-retroviral agents |
US20060088843A1 (en) | 2004-10-25 | 2006-04-27 | Reid Paul F | Modified venom and venom components as anti-retroviral agents |
US7902152B2 (en) | 2005-12-20 | 2011-03-08 | Receptopharm, Inc. | Use of cobratoxin as an analgesic |
US20080081048A1 (en) | 2006-10-02 | 2008-04-03 | Laurence Raymond | Production of modified neurotoxins |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US7758894B2 (en) | 2006-11-06 | 2010-07-20 | Receptopharm, Inc. | Modified elapid venoms as stimulators of the immune reaction |
US20090209468A1 (en) | 2006-12-19 | 2009-08-20 | Reid Paul F | Alpha-neurotoxin proteins with anti-inflammatory properties and uses thereof |
US7259237B1 (en) | 2006-12-29 | 2007-08-21 | Miller Kent D | Pan-antiviral peptides |
US20080254137A1 (en) | 2007-04-10 | 2008-10-16 | Raymond Laurence N | Treatment of autoimmune disorders using detoxified cobratoxin |
TW200914437A (en) | 2007-06-20 | 2009-04-01 | Ironwood Pharmaceuticals Inc | FAAH inhibitors |
WO2009105585A2 (en) | 2008-02-19 | 2009-08-27 | Myocept Inc. | Postsynaptically targeted chemodenervation agents and their methods of use |
WO2011017354A1 (en) | 2009-08-03 | 2011-02-10 | Paul Reid | Composition and method for oral delivery of cobra venom |
US7807635B1 (en) * | 2010-01-22 | 2010-10-05 | Miller Kent D | Pan-antiviral peptides for protein kinase inhibition |
US9220743B2 (en) * | 2010-01-22 | 2015-12-29 | Nuovo Biologics, Llc | Pan-antiviral peptides for protein kinase inhibition |
-
2010
- 2010-10-04 US US12/897,087 patent/US9220743B2/en not_active Expired - Fee Related
-
2011
- 2011-01-24 MX MX2012008448A patent/MX341547B/es active IP Right Grant
- 2011-01-24 AU AU2011207419A patent/AU2011207419A1/en not_active Abandoned
- 2011-01-24 EP EP11735292.2A patent/EP2525804B1/en not_active Not-in-force
- 2011-01-24 CA CA2787812A patent/CA2787812C/en active Active
- 2011-01-24 WO PCT/US2011/022200 patent/WO2011091344A1/en active Application Filing
-
2012
- 2012-07-22 IL IL221065A patent/IL221065A/en not_active IP Right Cessation
-
2015
- 2015-12-28 US US14/981,570 patent/US9555070B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9220743B2 (en) | 2015-12-29 |
EP2525804B1 (en) | 2017-12-06 |
IL221065A (en) | 2016-09-29 |
MX2012008448A (es) | 2013-02-07 |
US20110183884A1 (en) | 2011-07-28 |
AU2011207419A1 (en) | 2012-09-13 |
CA2787812C (en) | 2018-11-06 |
US9555070B2 (en) | 2017-01-31 |
WO2011091344A1 (en) | 2011-07-28 |
US20160199441A1 (en) | 2016-07-14 |
CA2787812A1 (en) | 2011-07-28 |
EP2525804A1 (en) | 2012-11-28 |
EP2525804A4 (en) | 2014-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ761094A (en) | Diaryl macrocycles as modulators of protein kinases | |
MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
MY172292A (en) | Vectors and sequences for the treatment of diseases | |
MY162741A (en) | Improved cancer therapy based on tumor associated antigens derived from cyclin D1 | |
WO2013134336A3 (en) | Inhibition of adaptor associated kinase 1 for the treatment of pain | |
IN2014DN09805A (es) | ||
MX365702B (es) | Inhibidores de pirazolil quinoxalina cinasa. | |
AU2011332810A8 (en) | Anti-IL-6 antibodies for the treatment of oral mucositis | |
NZ611108A (en) | Methods of treating fgf21-associated disorders | |
MX2015002371A (es) | Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos. | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
MY169987A (en) | Selective pi3k delta inhibitors | |
TW201712023A (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
SG194718A1 (en) | Novel compounds as modulators of protein kinases | |
MX2011012037A (es) | Compuestos de heteroarilo como inhibidores de pikk. | |
MX2010005651A (es) | Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento. | |
WO2010003520A3 (en) | Anti-tumor immunotherapy | |
MX2013011332A (es) | Combinaciones de compuestos inhibidores de akt y vemurafenib y metodos de uso de los mismos. | |
MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
EA201390520A1 (ru) | Замещенные соединения пиридазинкарбоксамида | |
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
UA100545C2 (ru) | Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |